ArticlePDF AvailableLiterature Review

Anophthalmia and microphthalmia

Authors:

Abstract and Figures

Anophthalmia and microphthalmia describe, respectively, the absence of an eye and the presence of a small eye within the orbit. The combined birth prevalence of these conditions is up to 30 per 100,000 population, with microphthalmia reported in up to 11% of blind children. High-resolution cranial imaging, post-mortem examination and genetic studies suggest that these conditions represent a phenotypic continuum. Both anophthalmia and microphthalmia may occur in isolation or as part of a syndrome, as in one-third of cases. Anophthalmia/microphthalmia have complex aetiology with chromosomal, monogenic and environmental causes identified. Chromosomal duplications, deletions and translocations are implicated. Of monogenic causes only SOX2 has been identified as a major causative gene. Other linked genes include PAX6, OTX2, CHX10 and RAX. SOX2 and PAX6 mutations may act through causing lens induction failure. FOXE3 mutations, associated with lens agenesis, have been observed in a few microphthalmic patients. OTX2, CHX10 and RAX have retinal expression and may result in anophthalmia/microphthalmia through failure of retinal differentiation. Environmental factors also play a contributory role. The strongest evidence appears to be with gestational-acquired infections, but may also include maternal vitamin A deficiency, exposure to X-rays, solvent misuse and thalidomide exposure. Diagnosis can be made pre- and post-natally using a combination of clinical features, imaging (ultrasonography and CT/MR scanning) and genetic analysis. Genetic counselling can be challenging due to the extensive range of genes responsible and wide variation in phenotypic expression. Appropriate counselling is indicated if the mode of inheritance can be identified. Differential diagnoses include cryptophthalmos, cyclopia and synophthalmia, and congenital cystic eye. Patients are often managed within multi-disciplinary teams consisting of ophthalmologists, paediatricians and/or clinical geneticists, especially for syndromic cases. Treatment is directed towards maximising existing vision and improving cosmesis through simultaneous stimulation of both soft tissue and bony orbital growth. Mild to moderate microphthalmia is managed conservatively with conformers. Severe microphthalmia and anophthalmia rely upon additional remodelling strategies of endo-orbital volume replacement (with implants, expanders and dermis-fat grafts) and soft tissue reconstruction. The potential for visual development in microphthalmic patients is dependent upon retinal development and other ocular characteristics.
Content may be subject to copyright.
BioMed Central
Page 1 of 8
(page number not for citation purposes)
Orphanet Journal of Rare Diseases
Open Access
Review
Anophthalmia and microphthalmia
Amit S Verma and David R FitzPatrick*
Address: MRC Human Genetics Unit, Edinburgh, UK
Email: Amit S Verma - Amit.Verma@hgu.mrc.ac.uk; David R FitzPatrick* - David.Fitzpatrick@hgu.mrc.ac.uk
* Corresponding author
Abstract
Anophthalmia and microphthalmia describe, respectively, the absence of an eye and the presence
of a small eye within the orbit. The combined birth prevalence of these conditions is up to 30 per
100,000 population, with microphthalmia reported in up to 11% of blind children. High-resolution
cranial imaging, post-mortem examination and genetic studies suggest that these conditions
represent a phenotypic continuum. Both anophthalmia and microphthalmia may occur in isolation
or as part of a syndrome, as in one-third of cases. Anophthalmia/microphthalmia have complex
aetiology with chromosomal, monogenic and environmental causes identified. Chromosomal
duplications, deletions and translocations are implicated. Of monogenic causes only SOX2 has been
identified as a major causative gene. Other linked genes include PAX6, OTX2, CHX10 and RAX.
SOX2 and PAX6 mutations may act through causing lens induction failure. FOXE3 mutations,
associated with lens agenesis, have been observed in a few microphthalmic patients. OTX2, CHX10
and RAX have retinal expression and may result in anophthalmia/microphthalmia through failure of
retinal differentiation. Environmental factors also play a contributory role. The strongest evidence
appears to be with gestational-acquired infections, but may also include maternal vitamin A
deficiency, exposure to X-rays, solvent misuse and thalidomide exposure. Diagnosis can be made
pre- and post-natally using a combination of clinical features, imaging (ultrasonography and CT/MR
scanning) and genetic analysis. Genetic counselling can be challenging due to the extensive range of
genes responsible and wide variation in phenotypic expression. Appropriate counselling is indicated
if the mode of inheritance can be identified. Differential diagnoses include cryptophthalmos,
cyclopia and synophthalmia, and congenital cystic eye. Patients are often managed within multi-
disciplinary teams consisting of ophthalmologists, paediatricians and/or clinical geneticists,
especially for syndromic cases. Treatment is directed towards maximising existing vision and
improving cosmesis through simultaneous stimulation of both soft tissue and bony orbital growth.
Mild to moderate microphthalmia is managed conservatively with conformers. Severe
microphthalmia and anophthalmia rely upon additional remodelling strategies of endo-orbital
volume replacement (with implants, expanders and dermis-fat grafts) and soft tissue
reconstruction. The potential for visual development in microphthalmic patients is dependent upon
retinal development and other ocular characteristics.
Published: 26 November 2007
Orphanet Journal of Rare Diseases 2007, 2:47 doi:10.1186/1750-1172-2-47
Received: 25 July 2007
Accepted: 26 November 2007
This article is available from: http://www.OJRD.com/content/2/1/47
© 2007 Verma and FitzPatrick; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Orphanet Journal of Rare Diseases 2007, 2:47 http://www.OJRD.com/content/2/1/47
Page 2 of 8
(page number not for citation purposes)
Disease names
Anophthalmia (OMIM 206900), Microphthalmia
(OMIM 309700)
Synonyms
Anophthalmos, microphthalmos, nanophthalmos, nano-
phthalmia
Definition and diagnostic criteria
The mean maximum axial lengths in the neonatal and
adult human eye are approximately 17 and 23.8 mm
respectively. Most of the post-natal growth of the eye
occurs within the first three years with posterior segment
expansion accounting for over 90% of post-natal growth.
The International Clearinghouse for Birth Defects Moni-
toring Systems defines anophthalmia and microphthal-
mia as "anophthalmos/microphthalmos: apparently
absent or small eyes. Some normal adnexal elements and
eyelids are usually present. In microphthalmia, the cor-
neal diameter is less than 10 mm, and the antero-poste-
rior diameter of the globe is less than 20 mm" [1].
Epidemiology
The birth prevalence of anophthalmia and microphthal-
mia has been generally estimated to be 3 and 14 per
100,000 population respectively, although other evidence
puts the combined birth prevalence of these malforma-
tions at up to 30 per 100,000 population [2,3]. Epidemi-
ological data suggests risk factors for these conditions are
maternal age over 40, multiple births [4,5], infants of low
birth weight and low gestational age [6]. There is no pre-
dilection with regards to race or gender [4,5]. Both anoph-
thalmia and microphthalmia are more commonly
bilateral; the exception appears to be isolated microph-
thalmia, which is usually unilateral [5]. Microphthalmia
is reported in 3.2 – 11.2% of blind children [7].
Clinical description
Anophthalmia refers to the absence of ocular tissue in the
orbit. In the absence of clinically apparent ocular tissue,
histological sectioning has shown residual neuroecto-
derm in some cases and hence terms such as 'true anoph-
thalmia', 'clinical anophthalmia' and 'extreme
microphthalmia' may in fact refer to what is in reality a
phenotypic range between anophthalmia and microph-
thalmia (figure 1). Clinically it seems reasonable to use
the term microphthalmia for an eye with axial length two
standard deviations below that of the population age-
adjusted mean; this typically correlates to an axial length
below 21 mm in adult eyes. Simple microphthalmia refers
to a structurally normal, small eye, and has been used
interchangeably with 'nanophthalmia' (though the latter
is particularly used when referring to a small eye with
microcornea, axial length <18 mm, and = 8D hyper-
metropia). The increased thickness of the sclera in these
eyes and the subsequent changes in blood flow are
believed to be responsible for the increased incidence of
uveal effusions and choroidal detachments seen. Micro-
phthalmia may also be associated with other ocular disor-
ders, in which case it is termed complex microphthalmia.
These ocular disorders may affect the anterior segment
(for example, sclerocornea and Peters anomaly) and/or
the posterior segment (for example, persistent hyperplas-
tic primary vitreous and retinal dysplasias). Both anoph-
thalmia and microphthalmia can occur in isolation or be
syndromic, as in about one-third of cases (see additional
files 1 and 2 for a review of syndromes associated with
Clinical appearance of anophthalmia (upper picture) and microphthalmia (lower picture)Figure 1
Clinical appearance of anophthalmia (upper picture) and
microphthalmia (lower picture).
Orphanet Journal of Rare Diseases 2007, 2:47 http://www.OJRD.com/content/2/1/47
Page 3 of 8
(page number not for citation purposes)
anophthalmia and microphthalmia respectively). Learn-
ing disabilities are seen in approximately one-fifth of cases
[2]. Complex microphthalmia, in particular, exhibits wide
phenotypic variability.
Aetiology
The precise pathogenesis of anophthalmia and microph-
thalmia remains unknown. Mann [8] suggested anoph-
thalmia has its genesis early in gestation as a result of
failure of development of the anterior neural tube (second-
ary anophthalmia) or optic pit(s) to enlarge and form
optic vesicle(s) (primary anophthalmia). A third category,
consecutive or degenerative anophthalmia was applied to
cases where optic vesicles have degenerated and disap-
peared subsequent to formation. Observations of optic
nerves, chiasm, and/or tracts with anophthalmia may
indicate the regression of a partially developed eye rather
than aplasia of the optic vesicle(s), a view supported by
observations in an apparently anophthalmic orbit of
extraocular muscle insertion into a fibrous mass, possibly
representing an aborted eye [9]. Following observations
that the posterior segment of microphthalmic eyes are
more affected than the anterior, Weiss and colleagues
[10,11] suggested that post-natal ocular growth is crucial
and speculated that decreased size of the optic cup, altered
proteoglycans in the vitreous, low intraocular pressure
and abnormal growth factor production may all or in part
have a bearing on the pathogenesis of simple microph-
thalmia; whilst inadequate production of secondary vitre-
ous may result in complex microphthalmia. Some cases of
microphthalmia may be associated with a cyst; these are
believed to result from failure of the optic fissure to close
[12].
Epidemiological studies have predicted both heritable
and environmental factors in causing anophthalmia and
microphthalmia. This review focuses on heritable causes
as the evidence for environmental causes is both more cir-
cumstantial and accounts for a smaller proportion of
cases. Chromosomal duplications, deletions and translo-
cations have been implicated in both anophthalmia and
microphthalmia, and are typically associated with charac-
teristic syndromes (table 1). Of monogenic causes (table
2 shows selected genes with mutations linked to anoph-
thalmia/microphthalmia), only SOX2 has to date been
identified as a major causative gene for anophthalmia/
microphthalmia. Cytogenetic studies placed the locus at
3q26.3, and de novo heterozygous loss-of-function point
mutations have been shown to account for 10–20% of
severe bilateral anophthalmia/microphthalmia [13], the
most common phenotype being bilateral anophthalmia.
The 'SOX2 anophthalmia syndrome' encompasses sclero-
cornea, cataracts, persistent hyperplastic primary vitreous
and optic disc dysplasia as well as non-ocular features like
mental retardation, neurological abnormalities, facial
dysmorphisms, post-natal growth failure, oesophageal
pathology and anomalies of male genitalia [14,15].
PAX6, on chromosome 11p13, has been studied more
extensively than most other eye genes. In humans, heter-
Table 1: Chromosomal abnormalities associated with anophthalmia/microphthalmia [55,7].
Chromosomal Abnormality Other Features
Duplication 3q syndrome (3q21-ter dup) Learning difficulties, growth deficiency, hypertrichosis, craniosynostosis, cardiac defects, chest
deformities, genital abnormalities, umbilical hernia
4p- (Wolf-Hirschhorn syndrome) Growth deficiency, microcephaly, ocular hypertelorism, cranial asymmetry, learning difficulties,
epilepsy, cleft lip/palate, anterior segment dysgenesis
Duplication 4p syndrome Learning difficulties, epilepsy, growth deficiency, obesity, microcephaly, characteristic faces, genital
abnormalities, kyphoscoliosis
Deletion 7p15.1-p21.1 Cryptophthalmos, cleft lip/palate, choanal atresia
Trisomy 9 mosaic syndrome Joint contractures, congenital heart defects, prenatal growth deficiency, learning difficulties,
micrognathia, kyphoscoliosis
Duplication 10q syndrome Ptosis, short palpebral fissures, camptodactyly, learning difficulties, prenatal growth deficiency,
microcephaly, heart and kidney malformations
13q-, 13 ring Microcephaly, learning difficulties, bilateral retinoblastoma, cardiac defects, hypospadias,
cryptorchidism
Trisomy 13 (Patau syndrome) Holoprosencephaly, moderate microcephaly, coloboma, retinal dysplasia, cyclopia, cleft lip/palate,
cardiac defects, genital abnormalities, 86% die within one year.
Deletion 14q22.1-q23.2 Pituitary hypoplasia.
18q- Midface hypoplasia, small stature, learning difficulties, hypotonia, nystagmus, conductive deafness,
microcephaly, midface hypoplasia, genital abnormalities
Trisomy 18 (Edwards syndrome) Polyhydramnios, single umbilical artery, small placenta, low foetal activity, learning difficulties,
hypertonicity, hypoplasia of skeletal muscle, subcutaneous, adipose tissue, prominent occiput, low-
set malformed auricles, micrognathia, cardiac defects
Triploidy syndrome Large placenta with hydatidiform changes, growth deficiency, syndactyly, congenital heart defects,
brain anomalies/holoprosencephaly
Orphanet Journal of Rare Diseases 2007, 2:47 http://www.OJRD.com/content/2/1/47
Page 4 of 8
(page number not for citation purposes)
ozygous loss-of-function mutations typically produce ani-
ridia (OMIM 106210), a congenital panocular
malformation associated with severe visual impairment;
however PAX6 was also the first gene implicated in
human anophthalmia [16]. Although PAX6 mutations are
an extremely rare cause of anophthalmia, there has
recently been interest in a possible co-operative role
between PAX6 and SOX2. Kondoh and colleagues [17]
have shown that PAX6 and SOX2 co-bind to a regulatory
element driving lens induction in the chick, which sug-
gests that lens induction failure could be responsible for
microphthalmia in patients with mutations in these genes
[9]. PAX6 and SOX2 interactions have since been shown
to also drive lens induction in mammals through their
action on the γ-crystallin gene (V van Heyningen, personal
communication). Ultrasound bimicroscopy studies are
required to determine if aphakia is commonly associated
in microphthalmic SOX2 cases. As expected with genes
expressed in the developing brain, patients with inherited
PAX6 and SOX2 mutations exhibit CNS malformations in
addition to dominantly inherited anophthalmia/micro-
phthalmia [18,9]. Interestingly mutations within the
FOXE3 gene (on chromosome 1p32), associated with
congenital primary aphakia (OMIM 610256), were
observed in three siblings with microphthalmia; in all
three cases the phenotype was believed to be secondary to
lens agenesis [19].
Mutations in three genes with retinal expression are asso-
ciated with anophthalmia/microphthalmia, possibly
through failure of retinal differentiation. Heterozygous
loss-of-function mutations of OTX2 (on chromosome
14q22, autosomal dominant inheritance) have been
shown to be associated with a wide range of ocular disor-
ders from anophthalmia and microphthalmia to retinal
defects. CNS malformations and mental retardation are
common in patients with OTX2 mutations [20,9]. RAX,
located on chromosome 18q21.32, is linked to about 2%
of inherited anophthalmia/microphthalmia [21]. Simi-
larly, CHX10 mutations (chromosome 14q24.3) account
for about 2% of isolated microphthalmia [22]; mutations
in both genes characteristically presenting with recessively
inherited phenotypes.
Two syndromes with broad phenotypes have been
described recently in association with anophthalmia.
GLI2 mutations had originally been described in the con-
text of holoprosencephaly and polydactyly, however there
has been a case reporting a missense mutation in a patient
with asymmetrical genu and callosal agenesis co-existing
with anophthalmia, thereby extending the phenotype
[23]. Anophthalmia with congenital heart defects, pulmo-
nary abnormalities, diaphragmatic hernia and learning
difficulties have been described in patients with muta-
tions of the STRA6 gene [24]. Our knowledge of genes
associated with microphthalmia has also increased; com-
plex microphthalmia in association with genetic cataracts
has been attributed to mutations in the CRYBA4 gene
[25]. In addition to these putative genes, several loci have
been identified with autosomal dominant microphthal-
mia mapping to 15q12-15 [26], autosomal recessive
microphthalmia mapping to 14q32 [27,28] and X-linked
anophthalmia mapping to Xq27-28 [29].
Over the past several years, there has been an increased
awareness of environmental factors associated with ano-
phthalmia/microphthalmia. In 1993, the UK media
reported clusters of anophthalmia and microphthalmia
patients, speculating that these conditions may be con-
nected to the pesticide Benomyl. Studies specifically
designed to look at this issue found no definitive causal
link [30-33]. The strongest evidence for environmental
causes is for gestational-acquired infections, with rubella,
toxoplasmosis, varicella and cytomegalovirus implicated
[30,34]. Other viruses in the herpes-zoster family have
also been linked, as have parvovirus B19, influenza virus,
and coxsackie A9 [35,36]. Non-infectious causes have
been postulated and include maternal vitamin A defi-
ciency [37], fever, hyperthermia, exposure to X-rays, sol-
vent misuse and exposure to drugs like thalidomide,
warfarin and alcohol [30].
Diagnostic methods
The diagnosis is usually based upon clinical and imaging
criteria, and may be confirmed on histology if post-mor-
tem is performed. Establishing a specific cause involves
undertaking a comprehensive medical history, physical
Table 2: Ocular phenotypes associated with gene mutations linked to anophthalmia/microphthalmia.
Gene Locus (Inheritance) Major (and selected less common) Human Ocular Phenotype(s) OMIM [54]
SOX2 3q26.3-q27 (AD) Anophthalmia/microphthalmia 184429
PAX6 11p13 (AD) Aniridia, (Peters anomaly, autosomal dominant keratopathy, foveal hypoplasia, optic
nerve malformations, anophthalmia)
607108
OTX2 14q22 (AD) Anophthalmia/microphthalmia, (retinal dysplasia, optic nerve malformations) 600037
RAX 18q21.3 (AR) Anophthalmia/microphthalmia 601881
CHX10 14q24.3 (AR) Microphthalmia 142993
FOXE3 1p32 Anterior segment dysgenesis, congenital primary aphakia 601094
CRYBA4 22q11.2-q13.1 (AD) Autosomal dominant cataract, (microphthalmia) 123631
Orphanet Journal of Rare Diseases 2007, 2:47 http://www.OJRD.com/content/2/1/47
Page 5 of 8
(page number not for citation purposes)
examination, family history, karyotyping and molecular
genetic testing, imaging, renal ultrasonography, and audi-
ology.
Ophthalmological assessment
Anophthalmia can potentially be a difficult clinical diag-
nosis to make. Microphthalmia is usually diagnosed by
inspection and palpation of the eye through the lids. The
diagnosis is aided by measurements of corneal diameter,
which ranges from 9–10.5 mm in neonates and 10.5–12
mm in adults. Microphthalmia with cyst usually presents
with lower lid bulging. Electrodiagnostic tests may be val-
uable, particularly in cases of microphthalmia where reti-
nal development has been unaffected. Eye examination of
both parents should be undertaken and a careful family
history of eye anomalies sought.
Paediatric and clinical genetics assessment
Because of the wide phenotypic spectrum associated with
anophthalmia/microphthalmia, it is vital to assess these
patients within multi-disciplinary teams that include pae-
diatricians and clinical geneticists. Further investigations
are dependent upon the clinical picture. If no syndrome is
identified in infancy, further examination after another
three or four years is desirable as many syndromes
become more apparent by this age.
Imaging
Ultrasound is most commonly used to determine the
length of the globe in microphthalmic eyes.
CT and MR scans facilitate the diagnosis of anophthalmia.
Both scans show the absence of a globe within the orbit
although soft amorphous tissue may be discerned (inter-
mediate T1 signal intensity and low T2 signal intensity on
MR scan, intermediate density on CT scan). Neural tissue
forming the visual pathway and extraocular muscles are
variably present (figure 2) [38-40]. Orbital dimensions
and volume are both reduced [38]. Simple microphthal-
mia shows as a normal albeit small globe, with normal
signal/density characteristics of lens and vitreous, in a
smaller orbit than normal.
Differential diagnosis
Cryptophthalmos refers to completely fused eyelid margins,
without lashes. These cases can be associated with both
microphthalmia and microcornea. It is often bilateral and
may be syndromic.
Cyclopia (total) and synophthalmia (partial) represent
degrees of fusion of the optic vesicles thereby preventing
the development of separate eyes. They correspond to
neural maldevelopments incompatible with life.
In contrast to microphthalmia with cyst, which results
from failure of the optic fissure to close, a congenital cystic
eye may develop from failure of the optic vesicle to invagi-
nate [12]. At birth, the cystic eye may resemble anophthal-
mia, however with post-natal expansion, a bulge may
appear behind the eyelids.
Genetic counselling
Genetic counselling is challenging both from the perspec-
tive of the extensive range of genes responsible for anoph-
thalmia/microphthalmia and the wide variation in
phenotypic expression. Only SOX2 has thus far been iden-
tified as a major anophthalmia/microphthalmia gene,
with mutations primarily arising de novo. The picture is
further complicated by observations of phenotypically
normal parents carrying loss of function SOX2 or OTX2
mutations [41,20]. Mosaicism and/or variable penetrance
render prediction of recurrence risk difficult in these
monogenic anophthalmia/microphthalmia cases. In gen-
eral, if the mode of inheritance can be identified, then
appropriate counselling is indicated. The empiric risk to
siblings without a clear aetiology or family history is
10–15%, assuming inheritance accounts for half of cases
with the other half occurring sporadically [7]. Chromo-
somal abnormalities associated with anophthalmia/
microphthalmia tend to be associated with distinct co-
morbidities and give rise to specific syndromes. If a
patient has a numerical chromosomal abnormality, the
parents can be expected to be entirely normal whilst sib-
T2-weighted MR scan of a patient with unilateral anophthal-miaFigure 2
T2-weighted MR scan of a patient with unilateral
anophthalmia. Note the presence of amorphous tissue and
structures resembling extraocular muscles within the anoph-
thalmic right orbit. The right optic nerve/chiasm junction
appears attenuated rather than absent suggesting possible
residual optic nerve neural tissue.
Orphanet Journal of Rare Diseases 2007, 2:47 http://www.OJRD.com/content/2/1/47
Page 6 of 8
(page number not for citation purposes)
lings are at a slightly increased risk of having a similar
chromosomal abnormality, with similar or dissimilar
phenotype [7]. If a patient has a structurally unbalanced
chromosomal constitution, the parents may have bal-
anced chromosomal rearrangements and other siblings
will be at a higher risk, though this will depend upon the
specific rearrangement. If neither parent has any rear-
rangement, the risk to siblings is virtually negligible [7].
Antenatal diagnosis
Chromosome analysis
Cytogenetic studies are possible upon amniotic fluid foe-
tal cells (usually withdrawn after 14 weeks of gestation) or
on chorionic villus sampling specimens (at about 10 to 12
weeks). The power of these techniques in facilitating the
pre-natal diagnosis of anophthalmia/microphthalmia
was elegantly demonstrated by Guichet and colleagues
(2004) [42]. In a foetus with severe intrauterine growth
retardation and bilateral anophthalmia on a 24-week
ultrasound scan, they demonstrated a 46, XX,
del(3)(q26.3q28) interstitial deletion of the long arm of
chromosome 3 on 650 band karyotype. FISH analysis
confirmed the interstitial deletion of 3q27 encompassing
the SOX2 locus.
Ultrasonography
It is possible to detect anophthalmia/microphthalmia by
early second trimester [43], though more recent reports
place the limit at about 12 weeks with trans-vaginal ultra-
sound [44,45]. Foetal eyes are best scanned in the coronal,
axial and corono-axial planes and appear as symmetrical
structures on either side of the nose. Lenses appear as
smooth circular lines with hypoechogenic content on
axial and coronal views. Eye size can be measured upon
visualising the maximum coronal or axial planes of the
orbit, and compared against established eye growth charts
[46,47].
MRI
where available can be used to supplement ultrasonogra-
phy.
Management
Conservative
Detectable retinal function may be present in microph-
thalmia cases, particularly those associated with SOX2
mutations. It is important to refract these eyes and treat
any underlying amblyopia. In unilateral cases, the 'good'
eye must be protected and any visual deficit managed
appropriately.
Surgical
Surgical management can form the mainstay of anoph-
thalmia/microphthalmia treatment. The globe triples in
volume between birth and adolescence. The growth of the
bony orbit reflects growth of the globe [48]. Both congen-
ital anophthalmia and microphthalmia result in a small
volume orbit compared to age-matched controls [49],
potentially leading to the appearance of hemifacial asym-
metry. There is also evidence that enucleation (removal of
the globe) produces a reduction in orbital volume in both
children and adults [50,51]. Reconstructive strategies rely
upon the simultaneous management of both soft tissue
hypoplasia and asymmetric bone growth [52].
Treatment is usually started early to maximise the overall
development of these children. Mild/moderate microph-
thalmia is generally managed conservatively with inser-
tion of a conformer (like a prosthetic eye but not painted),
periodically increasing in size to allow for growth of the
orbit. Treatment for severe microphthalmia and anoph-
thalmia are usually started within weeks of life using con-
formers to enlarge the palpebral fissure, conjunctival cul-
de-sac and orbit [48]. Endo-orbital volume replacement
using implants of progressively increasing size can be used
to stimulate expansion of the developing bony orbit, usu-
ally after six months of age. Volume replacement using
implants and expanders can also be supplemented by the
use of dermis-fat grafts. Static orbital implants may need
to be changed between three and five times before puberty
and are associated with problems of wound dehiscence,
extrusion or inadequate stimulation of bony growth.
Expandable orbital implants were introduced as an effica-
cious means of stimulating bony growth and socket
enlargement. Inflatable expanders are limited by difficulty
maintaining orbital fixation for sustained expansion and
controlling the direction of expansion, whilst self-expand-
ing hydrogel spheres lose expansion force once fully
hydrated. Orbital osteotomies are indicated in more
severe cases [48,52]. Ocular prostheses are used when the
orbit has developed adequately, and are changed regularly
with further orbital expansion. Conjunctival sac and lid
reconstruction may be beneficial to the overall cosmetic
effect. Microphthalmia with cyst is often treated around
the age of five permitting the ophthalmic surgeon to take
advantage of the orbital expansion properties of the cyst
until the orbit is about 90% of the adult volume, whilst
allowing removal for cosmetic reasons at about the time
the child starts school. Surgical excision with preceding
decompression is commonly performed, the cyst may also
be aspirated but the recurrence rate is higher [53].
Prognosis
The potential for visual development depends upon the
degree of retinal development and other ocular character-
istics in microphthalmic patients. Therapy aims to max-
imise existing vision and enhance cosmetic appearances
rather than improve sight.
Orphanet Journal of Rare Diseases 2007, 2:47 http://www.OJRD.com/content/2/1/47
Page 7 of 8
(page number not for citation purposes)
Unresolved issues
The aetiology of anophthalmia/microphthalmia under-
lies the entire developmental biology of ocular formation
and remains a field where our knowledge is increasing
exponentially. Despite the progresses made, much work is
still needed to understand the processes underlying these
complex diseases, which are a significant cause of child-
hood blindness. Even if these processes are elucidated in
the future, novel therapeutic approaches to prevent these
conditions from occurring could still be precluded by very
early ocular development in the foetus.
Abbreviations used
AD (autosomal dominant);
AR (autosomal recessive);
CNS (central nervous system);
CT (computerised tomography);
MR (magnetic resonance);
MRI (magnetic resonance imaging);
OMIM (Online Mendelian Inheritance in Man [54]).
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
ASV drafted the manuscript and both authors subse-
quently revised the manuscript for intellectual content.
Additional material
Acknowledgements
We gratefully acknowledge those patients who have permitted the usage of
their clinical pictures to illustrate the manuscript.
References
1. International Clearinghouse for Birth Defects Monitoring Systems:
Annual Report 2003 Rome: International Centre on Birth Defects;
2003.
2. Morrison D, FitzPatrick D, Hanson I, Williamson K, van Heyningen V,
Fleck B, Jones I, Chalmers J, Campbell H: National study of micro-
phthalmia, anophthalmia, and coloboma (MAC) in Scotland:
investigation of genetic aetiology. J Med Genet 2002, 39:16-22.
3. Campbell H, Holmes E, MacDonald S, Morrison D, Jones I: A cap-
ture-recapture model to estimate prevalence of children
born in Scotland with developmental eye defects. J Cancer Epi-
demiol Prev 2002, 7:21-28.
4. Shaw GM, Carmichael SL, Yang W, Harris JA, Finnell RH, Lammer EJ:
Epidemiologic characteristics of anophthalmia and bilateral
microphthalmia among 2.5 million births in California,
1989–1997. Am J Med Genet A 2005, 137:36-40.
5. Kallen B, Robert E, Harris J: The descriptive epidemiology of
anophthalmia and microphthalmia. Int J Epidemiol 1996,
25:1009-1016.
6. Forrester MB, Merz RD: Descriptive epidemiology of anoph-
thalmia and microphthalmia, Hawaii, 1986–2001. Birth Defects
Res A Clin Mol Teratol 2006, 76:187-92.
7. Anophthalmia/Microphthalmia Overview [http://www.gene
clinics.org/profiles/anophthalmia-ov/index.html]
8. Mann I: The Developmental Basis of Eye Malformations. Phil-
adelphia: JB Lippincott; 1953.
9. Fitzpatrick DR, van Heyningen V: Developmental eye disorders.
Curr Opin Genet Dev 2005, 15:348-353.
10. Weiss AH, Kousseff BG, Ross EA, Longbottom J: Simple microph-
thalmos. Arch Ophthalmol 1989, 107:1625-1630.
11. Weiss AH, Kousseff BG, Ross EA, Longbottom J: Complex micro-
phthalmos. Arch Ophthalmol 1989, 107:1619-1624.
12. Guthoff R, Klein R, Lieb WE: Congenital cystic eye. Graefes Arch
Clin Exp Ophthalmol 2004, 242:268-271.
13. Fantes JA, Ragge NK, Lynch SA, McGill NI, Collin JRO, Howard-Pee-
bles PN, Hayward C, Vivian AJ, Williamson KA, van Heyningen V, Fit-
zPatrick DR: Mutations in SOX2 cause anophthalmia. Nat Genet
2003, 33:461-463.
14. Ragge NK, Lorenz B, Schneider A, Bushby K, de Sanctis L, de Sanctis
U, Salt A, Collin JR, Vivian AJ, Free SL, Thompson P, Williamson KA,
Sisodiya SM, van Heyningen V, Fitzpatrick DR: SOX2 anophthalmia
syndrome. Am J Med Genet A 2005, 135:1-8.
15. Williamson KA, Hever AM, Rainger J, Rogers RC, Magee A, Fiedler Z,
Keng WT, Sharkey FH, McGill N, Hill CJ, Schneider A, Messina M,
Turnpenny PD, Fantes JA, van Heyningen V, FitzPatrick DR: Muta-
tions in SOX2 cause anophthalmia-esophageal-genital
(AEG) syndrome. Hum Mol Genet 2006, 15:1413-1422.
16. Glaser T, Jepeal L, Edwards JG, Young SR, Favor J, Maas RL: PAX6
gene dosage effect in a family with congenital cataracts, ani-
ridia, anophthalmia and central nervous system defects. Nat
Genet 1994, 7:463-471.
17. Kondoh H, Uchikawa M, Kamachi Y: Interplay of Pax6 and SOX2
in lens development as a paradigm of genetic switch mecha-
nisms for cell differentiation. Int J Dev Biol 2004, 48:819-827.
18. Sisodiya SM, Ragge NK, Cavalleri GL, Hever A, Lorenz B, Schneider
A, Williamson KA, Stevens JM, Free SL, Thompson PJ, van Heyningen
V, Fitzpatrick DR: Role of SOX2 mutations in human hippoc-
ampal malformations and epilepsy. Epilepsia 2006, 47:534-542.
19. Valleix S, Niel F, Nedelec B, Algros MP, Schwartz C, Delbosc B,
Delpech M, Kantelip B: Homozygous nonsense mutation in the
FOXE3 gene as a cause of congenital primary aphakia in
humans. Am J Hum Genet 2006, 79:358-364.
20. Ragge NK, Brown AG, Poloschek CM, Lorenz B, Henderson RA,
Clarke MP, Russell-Eggitt I, Fielder A, Gerrelli D, Martinez-Barbera JP,
Ruddle P, Hurst J, Collin JR, Salt A, Cooper ST, Thompson PJ, Sisodiya
SM, Williamson KA, FitzPatrick DR, van Heyningen V, Hanson IM:
Heterozygous mutations of OTX2 cause severe ocular mal-
formations. Am J Hum Genet 2005, 76:1008-1022.
21. Voronina VA, Kozhemyakina EA, O'Kernick CM, Kahn ND, Wenger
SL, Linberg JV, Schneider AS, Mathers PH: Mutations in the human
Additional file 1
Syndromes associated with anophthalmia. A description of the clinical
syndromes known to be associated with anophthalmia. This table also
includes known (or postulated) genetic associations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1172-2-47-S1.doc]
Additional file 2
Syndromes associated with microphthalmia. A description of the clinical
syndromes known to be associated with microphthalmia. This table also
includes known (or postulated) genetic associations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1750-
1172-2-47-S2.doc]
Publish with BioMed Central and ever y
scientist can read your work free of charge
"BioMed Central will be the most significant development for
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Orphanet Journal of Rare Diseases 2007, 2:47 http://www.OJRD.com/content/2/1/47
Page 8 of 8
(page number not for citation purposes)
RAX homeobox gene in a patient with anophthalmia and
sclerocornea. Hum Mol Genet 2004, 13:315-322.
22. Ferda Percin E, Ploder LA, Yu JJ, Arici K, Horsford DJ, Rutherford A,
Bapat B, Cox DW, Duncan AM, Kalnins VI, Kocak-Altintas A, Sowden
JC, Traboulsi E, Sarfarazi M, McInnes RR: Human microphthalmia
associated with mutations in the retinal homeobox gene
CHX10. Nat Genet 2000, 25:397-401.
23. Rahimov F, Ribeiro LA, de Miranda E, Richieri-Costa A, Murray JC:
GLI2 mutations in four Brazilian patients: how wide is the
phenotypic spectrum? Am J Med Genet A 2006, 140:2571-2576.
24. Pasutto F, Sticht H, Hammersen G, Gillessen-Kaesbach G, Fitzpatrick
DR, Nurnberg G, Brasch F, Schirmer-Zimmermann H, Tolmie JL, Chi-
tayat D, Houge G, Fernandez-Martinez L, Keating S, Mortier G, Hen-
nekam RC, von der Wense A, Slavotinek A, Meinecke P, Bitoun P,
Becker C, Nurnberg P, Reis A, Rauch A: Mutations in STRA6
cause a broad spectrum of malformations including anoph-
thalmia, congenital heart defects, diaphragmatic hernia,
alveolar capillary dysplasia, lung hypoplasia, and mental
retardation. Am J Hum Genet 2007, 80:550-560.
25. Billingsley G, Santhiya ST, Paterson AD, Ogata K, Wodak S, Hosseini
SM, Manisastry SM, Vijayalakshmi P, Gopinath PM, Graw J, Heon E:
CRYBA4, a novel human cataract gene, is also involved in
microphthalmia. Am J Hum Genet 2006, 79:702-709.
26. Morle L, Bozon M, Zech JC, Alloisio N, Raas-Rothschild A, Philippe C,
Lambert JC, Godet J, Plauchu H, Edery P: A locus for autosomal
dominant colobomatous microphthalmia maps to chromo-
some 15q12-q15. Am J Hum Genet 2000, 67:1592-1597.
27. Bessant DA, Khaliq S, Hameed A, Anwar K, Mehdi SQ, Payne AM,
Bhattacharya SS: A locus for autosomal recessive congenital
microphthalmia maps to chromosome 14q32. Am J Hum Genet
1998, 62:1113-1116.
28. Bessant DA, Anwar K, Khaliq S, Hameed A, Ismail M, Payne AM,
Mehdi SQ, Bhattacharya SS: Phenotype of autosomal recessive
congenital microphthalmia mapping to chromosome 14q32.
Br J Ophthalmol 1999, 83:919-922.
29. Graham CA, Redmond RM, Nevin NC: X-linked clinical anoph-
thalmos. Localization of the gene to Xq27-Xq28. Ophthalmic
Paediatr Genet 1991, 12:43-48.
30. Dolk H, Busby A, Armstrong BG, Walls PH: Geographical varia-
tion in anophthalmia and microphthalmia in England,
1988–94. BMJ 1998, 317:905-909.
31. Spagnolo A, Bianchi F, Calabro A, Calzolari E, Clementi M, Mastroi-
acovo P, Meli P, Petrelli G, Tenconi R: Anophthalmia and beno-
myl in Italy: a multicenter study based on 940,615 newborns.
Reprod Toxicol 1994, 8:397-403.
32. Bianchi F, Calabro A, Calzolari E, Mastroiacovo PP, Petrelli G, Spag-
nolo A, Tenconi R: Clusters of anophthalmia. No link with ben-
omyl in Italy. BMJ 1994, 308:205.
33. Kristensen P, Irgens LM: Clusters of anophthalmia... or in Nor-
way. BMJ 1994, 308:205-206.
34. Warburg M: An update on microphthalmos and coloboma. A
brief survey of genetic disorders with microphthalmos and
coloboma. Ophthalmic Paediatr Genet 1991, 12:57-63.
35. Weiland HT, Vermey-Keers C, Salimans MM, Fleuren GJ, Verwey RA,
Anderson MJ: Parvovirus B19 associated with fetal abnormal-
ity. Lancet 1987, 1(8534):682-683.
36. Knox EG, Lancashire RJ: Epidemiology of congenital malforma-
tions. London: HMSO; 1991.
37. O'Keefe M, Webb M, Pashby RC, Wagman RD: Clinical anophthal-
mos. Br J Ophthalmol 1987, 71:635-638.
38. Albernaz VS, Castillo M, Hudgins PA, Mukherji SK: Imaging findings
in patients with clinical anophthalmos. Am J Neuroradiol 1997,
18:555-561.
39. Sanjari MS, Ghasemi Falavarjani K, Parvaresh MM, Kharazi HH, Kashk-
ooli MB: Bilateral aplasia of the optic nerve, chiasm, and
tracts in an otherwise healthy infant. Br J Ophthalmol 2006,
90:513-514.
40. Aktekin M, Oz O, Saygili MR, Kurtoglu Z: Bilateral congenital ano-
phthalmos and agenesis of the optic pathways. Yonsei Med J
2005, 46:296-299.
41. Faivre L, Williamson KA, Faber V, Laurent N, Grimaldi M, Thauvin-
Robinet C, Durand C, Mugneret F, Gouyon JB, Bron A, Huet F, Hay-
ward C, Heyningen V, Fitzpatrick DR: Recurrence of SOX2 ano-
phthalmia syndrome with gonosomal mosaicism in a
phenotypically normal mother. Am J Med Genet A 2006,
140:636-639.
42. Guichet A, Triau S, Lepinard C, Esculapavit C, Biquard F, Descamps
P, Encha-Razavi F, Bonneau D: Prenatal diagnosis of primary
anophthalmia with a 3q27 interstitial deletion involving
SOX2. Prenat Diagn 2004, 24:828-832.
43. Bronshtein M, Zimmer E, Gershoni-Baruch R, Yoffe N, Meyer H, Blu-
menfeld Z: First- and second-trimester diagnosis of fetal ocu-
lar defects and associated anomalies: report of eight cases.
Obstet Gynecol 1991, 77:443-449.
44. Chen CP, Wang KG, Huang JK, Chang TY, Lin YH, Chin DT, Tzen CY,
Wang W: Prenatal diagnosis of otocephaly with microphthal-
mia/anophthalmia using ultrasound and magnetic resonance
imaging. Ultrasound Obstet Gynecol 2003, 22:214-215.
45. Mashiach R, Vardimon D, Kaplan B, Shalev J, Meizner I: Early sono-
graphic detection of recurrent fetal eye anomalies. Ultrasound
Obstet Gynecol 2004, 24:640-643.
46. Blazer S, Zimmer EZ, Mezer E, Bronshtein M: Early and late onset
fetal microphthalmia. Am J Obstet Gynecol 2006, 194:1354-1359.
47. Jeanty P, Dramaix-Wilmet M, Van Gansbeke D, van Regemorter N,
Rodesch F: Fetal ocular biometry by ultrasound. Radiology 1982,
143:513-516.
48. Clauser L, Sarti E, Dallera V, Galiè M: Integrated reconstructive
strategies for treating the anophthalmic orbit. J Craniomaxillo-
fac Surg 2004, 32:279-290.
49. Kennedy RE: Growth retardation and volume determinations
of the anophthalmic orbit. Trans Am Ophthalmol Soc 1972,
70:277-297.
50. Kennedy RE: The Effect of Early Enucleation on the Orbit in
Animals and Humans. Trans Am Ophthalmol Soc 1964, 62:459-510.
51. Hintschich C, Zonneveld F, Baldeschi L, Bunce C, Koornneef L: Bony
orbital development after early enucleation in humans. Br J
Ophthalmol 2001, 85:205-208.
52. Tse DT, Pinchuk L, Davis S, Falcone SF, Lee W, Acosta AC, Hernan-
dez E, Lee E, Parel JM: Evaluation of an integrated orbital tissue
expander in an anophthalmic feline model. Am J Ophthalmol
2007, 143:317-327.
53. McLean CJ, Ragge NK, Jones RB, Collin JR: The management of
orbital cysts associated with congenital microphthalmos and
anophthalmos. Br J Ophthalmol 2003, 87:860-863.
54. Online Mendelian Inheritance in Man [http://
www.ncbi.nlm.nih.gov/Omim]
55. Brooks BP, Traboulsi EI: Congenital Malformations of the Eye.
In Duane's Clinical Ophthalmology on CD-ROM 2005 Edition Foundation
Volume 1, Chapter 40 Edited by: Tasman W, Jaeger EA. Philadelphia:
Lippincott.

Supplementary resources (2)

... Микрофтальм может вызвать глаукому и другие осложнения, затрагивающие сетчатку и сосудистую оболочку глаза. Врожденная катаракта со сложным микрофтальмом часто сочетается с глазными или системными аномалиями, а пациенты после операции склонны к вторичной глаукоме, помутнению роговицы и другим серьезным осложнениям [4]. В зависимости от размеров глаза различают 3 степени микрофтальма: 1 степень ПЕРЕДОВАЯ ОФТАЛЬМОЛОГИЯ Том 8 | Выпуск 2 | 2024 ПЕРЕДОВАЯ ОФТАЛЬМОЛОГИЯ -уменьшение одного или двух вышеуказанных размеров на 1,0-1,5мм по сравнению с возрастной нормой; 2 степень -уменьшение на 2,0-2,5мм; 3 степень -уменьшение на 3мм и более. ...
Article
Full-text available
Актуальность. Врожденная катаракта часто сочетается с другими патологическими изменениями органа зрения, которые наблюдаются у 36,8-77,3% детей: косоглазие, нистагм, микрофтальм, микрокорнеа и другие аномалии роговицы, а также стекловидного тела, сосудистой оболочки, сетчатки и зрительного нерва. Цель исследования. Изучить особенности дифференцированного подхода к хирургическому лечению и реабилитации детей с катарактой сочетанной с микрофтальмом. Материалы и методы. Проведен анализ историй болезни 72 детей (117 глаз) с установленным диагнозом врожденная катаракта, находившихся на стационарном лечении в глазном отделении клиники ТашПМИ за период с 2016 по 2023 в возрасте от 3 месяцев до 14 лет. Мальчики составили 42%, девочки 58%. Пациентам были проведены офтальмологические, клинико-лабораторные методы исследования и консультации узких специалистов. Результаты и заключение. Детям с микрофтальмом оперативное лечение проводилось в максимально ранние сроки. На первом этапе выполнялась экстракапсулярная экстракция катаракты (ЭЭК). На втором этапе производилась имплантация ИОЛ с размещением линзы в цилиарной борозде при подходящем состоянии глаз. В раннем послеоперационном периоде наблюдалась воспалительная реакция в виде фиброзно-экссудативной реакцией в 49% случаев, в позднем послеоперационном периоде – сублюксация ИОЛ в 9 %, офтальмогипертензия в 18% случаев соответственно. Таким образом, детям с врожденной катарактой и сопктствующим микрофтальмом необходимо раннее хирургическое вмешательство до 1 года – 1 этап, включающее проведение экстракции катаракты, в дальнейшем проведение 2 этапа- имплантации ИОЛ. Необходимо проведение постоянного динамического наблюдения, учитывая высокий процент послеоперационных осложнений.
... The prevalence of congenital microphthalmia is estimated to be 0.2-3.0 per 10,000 individuals, with nonocular involvement reported in ∼80% of cases (Llorente-Gonzalez et al. 2011;Searle et al. 2018). In humans, at least 30 types of syndromic microphthalmia have been described, with at least 40 associated genetic loci identified; nonocular manifestations include nose and facial dysmorphia, dental malformations, agenesis of the brain, heart defects, mental retardation, and digital abnormalities, among others (Verma and Fitzpatrick 2007). ...
Article
Full-text available
In humans, the prevalence of congenital microphthalmia is estimated to be 0.2–3.0 for every 10,000 individuals, with nonocular involvement reported in ∼80% of cases. Inherited eye diseases have been widely and descriptively characterized in dogs, and canine models of ocular diseases have played an essential role in unraveling the pathophysiology and development of new therapies. A naturally occurring canine model of a syndromic disorder characterized by microphthalmia was discovered in the Portuguese water dog. As nonocular findings included tooth enamel malformations, stunted growth, anemia, and thrombocytopenia, we hence termed this disorder Canine Congenital Microphthalmos with Hematopoietic Defects. Genome-wide association study and homozygosity mapping detected a 2 Mb candidate region on canine chromosome 4. Whole-genome sequencing and mapping against the Canfam4 reference revealed a Short interspersed element insertion in exon 2 of the DNAJC1 gene (g.74,274,883ins[T70]TGCTGCTTGGATT). Subsequent real-time PCR-based mass genotyping of a larger Portuguese water dog population found that the homozygous mutant genotype was perfectly associated with the Canine Congenital Microphthalmos with Hematopoietic Defects phenotype. Biallelic variants in DNAJC21 are mostly found to be associated with bone marrow failure syndrome type 3, with a phenotype that has a certain degree of overlap with Fanconi anemia, dyskeratosis congenita, Shwachman–Diamond syndrome, Diamond–Blackfan anemia, and reports of individuals showing thrombocytopenia, microdontia, and microphthalmia. We, therefore, propose Canine Congenital Microphthalmos with Hematopoietic Defects as a naturally occurring model for DNAJC21-associated syndromes.
... Radiation exposure from X-rays during pregnancy can lead to significant changes during organogenesis due to radiation-induced cell death; common manifestations include microcephaly and microphthalmia [88,89]. In Zebrafish embryos, exposure to higher doses of radiation impacted the diameter of the eye and the inner nuclear cell layer and resulted in lens opacification [90,91]. ...
Article
Full-text available
The intricate steps of human ocular embryology are impacted by cellular and genetic signaling pathways and a myriad of external elements that can affect pregnancy, such as environmental, metabolic, hormonal factors, medications, and intrauterine infections. This review focuses on presenting some of these factors to recognize the multifactorial nature of ocular development and highlight their clinical significance. This review is based on English-language articles sourced from PubMed, Web of Science, and Google Scholar; keywords searched included “ocular development in pregnancy,” “ocular embryology,” “maternal nutrition,” “ophthalmic change,” and “visual system development.” While some animal models show the disruption of ocular embryology from these external factors, there are limited post-birth assessments in human studies. Much remains unknown about the precise mechanisms of how these external factors can disrupt normal ocular development in utero, and more significant research is needed to understand the pathophysiology of these disruptive effects further. Findings in this review emphasize the importance of additional research in understanding the dynamic association between factors impacting gestation and neonatal ocular development, particularly in the setting of limited resources.
... The rehabilitation of the patient who has suffered the psychological trauma of an ocular loss requires a prosthesis that will provide the optimum cosmetic and functional result [2]. The etiology of inherent ocular deformities could be because of hereditary changes, maternal nourishment deficiency mainly vitamin A, and maternal contamination during pregnancy [5][6][7]. Among all the eye defects, the condition called phthisis bulbi, demands a major place in and around the world. ...
Article
An ocular prosthesis is an artificial eye that replaces an absent natural eye following an enucleation, evisceration or orbital exenteration. The prosthesis fits over an orbital implant and under the eyelids that covers the structures in the eye socket. It is a non-optical device designed only to improve the cosmesis of an individual with anophthalmic socket or disfigured eye. A normal facial appearance is one of the inherent human traits, if any changed or lost challenges physical, social, mental well-being, self-confidence and psychological influence on the affected people. The loss of an eye is a severe psychological trauma with negative impact on the quality of life of the patient. It is quite challenging to restore the normal look of the patient for bringing him to normality in society. In this view, an ocular prosthetic eye helps to improve the quality of life, satisfaction and appearance of affected eye to any injury or disease of the patient. It is given to uplift the patient’s behavioral, mental status and improve the confidence especially in children. Today, most artificial eyes are made of medical grade plastic acrylate (polymethyl methacrylate material) with an average life of about 2-3years depending upon the way that people use it. It is commonly known as “Device or Scleral Shell or Glass Eye or Fake Eye”. The children require more frequent replacement of the prosthetic eye due to rapid growth changes in the eye. The construction of an ocular prosthesis in the case of congenital and acquired anophthalmia differs in etiology but many concepts of management for a child are the same as for an adult. An early intervention with ocular prosthesis can stimulate orbital growth and prevent facial asymmetry.
... Other linked genes include PAX6, OTX2, CHX10 and RAX. SOX2 and PAX6 mutations may act through causing lens 12 induction failure. One hypothesis is that microphthalmos, anophthalmos and coloboma are due to interactions between genes controlling retinoic acid signalling and maternal vitamin A deciency during early fetal development, this may explain its prevalence in 13 Indian Children. ...
Article
Aim: Method: To determine the causes of blindness among children in the eastern region of Maharashtra. This is an observational cross – sectional study where 634 children less than 16 years of age with visual acuity of less than 6/60 in better eye (NPCB) were included. All patients coming to ophthalmology OPD and children referred from school heath camps from august 2019- july2022 were included in this study. The WHO/PBL eye examination record for children with blindness and low vision was referred to categorize the causes of blindness and to record the ndings, using the denitions in the coding instructions. Results: 634 children were included. Based on the anatomical site involved, whole globe anomalies contributed to about 41.8% followed by lenticular (24.45%) and corneal causes (19.6%). Vitamin A deciency was the most common cause of preventable blindness accounting for 12.6% and Cataract was the most common cause of treatable blindness (23.34). Almost half (46.68%) of the study population had either preventable or treatable causes of blindness A Conclusion: paradigm shift in causes of blindness has been observed over the years, however there's still a long way to go to reduce overall burden of childhood blindness especially in rural areas.
Article
Purpose: To report the long-term clinical outcomes of non-surgical treatment involving prosthetic eye wear in patients diagnosed with congenital microphthalmos.Methods: A retrospective review of the medical records of 20 patients was conducted. In total, 21 eyes were diagnosed with congenital microphthalmos between May 2008 and December 2022 at Seoul St. Mary’s Hospital in Korea.Results: This study included 20 patients (12 males and 8 females) with an average age of 4 months at diagnosis. The observed ophthalmic anomalies included two cases of congenital cataract, one of posterior embryotoxon, one of corneo-iris strand, four of iris coloboma, five of central corneal opacity, one of Peter's anomaly, and one of retrobulbar cyst. Accompanying systemic abnormalities were noted, such as lateral ventricle atrophy, corpus callosum atrophy, patent ductus arteriosus, atrial septal defect, and developmental language disorder. Genetic anomalies included anti SS-A/Ro antibody positivity, a 1:100 titer of anti-nuclear antibody, and a PAX6 mutation identified through next-generation sequencing. No specific family histories or pregnancy-related factors were noted. The average follow-up duration was 5.94 years (range: 1 month to 18 years), the average corneal diameter was 4.6 mm, the average axial length was 17.44 mm, the average age for first artificial eye trial was 5.96 years (range: 7 months to 19 years), and the average interval for artificial eye replacement was 22 months (range: 4 months to 5 years and 8 months).Conclusions: Twenty patients with congenital microphthalmos underwent gradual expansion of their prosthetic eyes by regular replacement and size increase without severe complications. This approach led to aesthetically and emotionally positive outcomes for the patients.
Chapter
Anophthalmia and microphthalmia (AM) are rare ocular developmental disorders in which one or both eyes are absent or abnormally small. Malformations can be limited to the globe, or involve the orbit, such as associated orbital cysts and/or insufficient development of the orbital bones and eyelids. Aetiology of AM is believed to be mainly genetic, with environmental, infectious, nutritional and other exogenous factors also playing a role. Recent advances in genetics have enhanced our understanding of the genetic basis of AM, as well as improving diagnosis and genetic counselling. A comprehensive ophthalmic and paediatric screening is required to detect any other anomalies, and imaging should be performed to assess the orbital content and the presence of an associated cyst. Management requires a multidisciplinary approach including oculoplastic surgeons, ocularists, paediatricians and geneticists. When there is no visual potential, the goal is to achieve the best possible aesthetic outcomes by early socket expansion, which is crucial for minimising the potential impact of AM on facial growth and development. Cosmetic rehabilitation can be achieved with conservative or surgical approaches, including ocular prostheses, socket or orbital expansion, with or without socket and/or eyelid reconstructive surgery. In AM with orbital cyst, the timing of cyst removal is important to avoid distortion of the periorbital tissues.
Article
Purpose To evaluate axial length (AL), orbital width (OW) and height (OH) development in congenital microphthalmia and anophthalmia (MICA) using serial ultrasonography measurements. Methods A longitudinal prospective cohort ( n = 74) of unilaterally and bilaterally affected MICA patients was followed from 2013 to 2022 at the university hospital in Amsterdam, the Netherlands. Clinical entity, age, severity category based on axial length, conformer treatment and intra‐orbital cysts were registered. The main outcome measures were the absolute and relative growth of AL, OW and OH. Surgical and intra‐orbital cyst cases were described separately. Results Absolute microphthalmic eye size increased in 27/49 (55%) unilateral MICA eyes, but growth arrest/decrease in the remaining could shift the case to a more severe category over time. A final affected/unaffected orbital symmetry ≥80% was seen in the large majority of unilateral cases (45/46 for OW, 43/46 for OH). Cases with AL < 10.5 mm had orbital symmetry <80% more often. Most orbital symmetry changes were seen in moderate and severe unilateral cases treated with 3D‐printed conformer therapy starting at age <1 year, with 6/10 (60%) symmetry increase, 30% unchanged symmetry and 10% symmetry decrease. All cases older than 6.5 years ( n = 6) did not show any change anymore, regardless of treatment. For bilateral and unilateral mild cases, orbital dimensions kept the same proportions during follow‐up, with or without conformer treatment. Conclusions Using severity categories in MICA based on relative AL may aid the decision to start conformer treatment, as most orbital symmetry changes were seen in moderate and severe unilateral cases receiving 3D‐printed conformer therapy that started under age 1.
Chapter
The development of ocular anterior segment structures is a precisely coordinated process that is determined by both genetic and environmental factors. In humans, this process begins from week six of gestation and is characterized by the formation of the lens placode from overlying surface ectoderm. The cornea is derived after lens detachment, while several waves of tissue invade the primary mesenchyme that lies behind the surface ectoderm, ultimately giving rise to an anterior epithelium and a posterior endothelium, with the corneal stroma laying between these layers. A number of genes that include transcription factors, nuclear proteins, structural proteins, and enzymes are known to be involved in this sophisticated process, and defects in these key genes may lead to severe congenital anterior segment dysgenesis (ASD).
Article
Full-text available
The human eye malformation aniridia results from haploinsufficiency of PAX6, a paired box DNA-binding protein. To study this dosage effect, we characterized two PAX6 mutations in a family segregating aniridia and a milder syndrome consisting of congenital cataracts and late onset corneal dystrophy. The nonsense mutations, at codons 103 and 353, truncate PAX6 within the N-terminal paired and C-terminal PST domains, respectively. The wild-type PST domain activates transcription autonomously and the mutant form has partial activity. A compound heterozygote had severe craniofacial and central nervous system defects and no eyes. The pattern of malformations is similar to that in homozygous Sey mice and suggests a critical role for PAX6 in controlling the migration and differentiation of specific neuronal progenitor cells in the brain.
Article
• Simple microphthalmos was diagnosed in 22 patients on the basis of a normal-appearing eye and a total axial length at least 2 SDs below the mean for age. Anterior segment length was normal in most patients while posterior segment length was at least 2 SDs below the mean in all patients, indicating that disproportionate reduction in posterior segment length accounted for the microphthalmos. The normal values for total axial length, anterior segment length, and posterior segment length were determined from the analysis of axial length measurements obtained from age-similar controls. Ten patients had isolated microphthalmos. One of them was diagnosed as having nanophthalmos on the basis of microcornea, total axial length less than 18 mm, and absence of systemic disease. Twelve patients had associated systemic disorders, such as fetal alcohol syndrome, myotonic dystrophy, and achondroplasia, which implicated decreased size of the optic cup, altered vitreous proteoglycans, low intraocular pressure, and abnormal release of growth factors in the pathogenesis of microphthalmos.
Article
• Forty patients were diagnosed as having complex microphthalmos on the basis of a malformed globe with a total axial length measurement at least 2 SDs below the mean for age-similar controls. Three had anterior segment dysgenesis; 4, congenital lens abnormalities; 14, chorioretinal colobomas; 12, persistent hyperplastic primary vitreous; 4, retinal dysplasia; and 3, complex malformations due to ipsilateral facial malformations. Measurements of total axial length indicated that complex microphthalmos was congenital and that postnatal growth of the malformed eye was similar to that of normal eyes. In most patients the anterior segment length was normal, while in all patients the posterior segment length was at least 2 SDs below the mean. Corneal diameter correlated significantly with total axial length (r2 =.57) and decreased linearly as total axial length decreased. In most patients in whom measurements were obtained, the lens and corneal power were increased, thereby compensating for decreased total axial length. We propose that inadequate production of secondary vitreous is the cause of the microphthalmos, given that the posterior segment was disproportionately reduced in size and the secondary vitreous is its predominant component. Evidence that each of the various ocular malformations can influence the production of secondary vitreous is presented.
Article
Heterozygous, de novo, loss-of-function mutations in SOX2 have been shown to cause bilateral anophthalmia. Here we provide a detailed description of the clinical features associated with SOX2 mutations in the five individuals with reported mutations and four newly identified cases (including the first reported SOX2 missense mutation). The SOX2-associated ocular malformations are variable in type, but most often bilateral and severe. Of the nine patients, six had bilateral anophthalmia and two had anophthalmia with contralateral microphthalmia with sclerocornea. The remaining case had anophthalmia with contralateral microphthalmia, posterior cortical cataract and a dysplastic optic disc, and was the only patient to have measurable visual acuity. The relatively consistent extraocular phenotype observed includes: learning disability, seizures, brain malformation, specific motor abnormalities, male genital tract malformations, mild facial dysmorphism, and postnatal growth failure. Identifying SOX2 mutations from large cohorts of patients with structural eye defects has delineated a new, clinically-recognizable, multisystem disorder and has provided important insight into the developmental pathways critical for morphogenesis of the eye, brain, and male genital tract
Article
Following the report on clusters of anophthalmia and microphthalmia in England and Wales their possible relation to the pesticide Benomyl, we analyzed the situation in Italy for the period 1986 to 1990 using data from the Italian registries of congenital malformations and national data on Benomyl use. Of 940,615 consecutive births, 33 cases of clinical anophthalmia and 78 cases of microphthalmia were reported (birth prevalence: 0.35 and 0.83/10,000). Birth prevalence by region for 18 of Italy's 20 political regions was evaluated for the two malformations, grouped together after exclusion of defects associated with chromosomal anomalies, no dishomogeneity in space or time among registries or among regions was observed for the study period. In no region was a statistically significant difference identified between observed and expected overall birth prevalence. Correlation analysis between the prevalence of micro/anophthalmia and Benomyl use by region showed a negative, nonsignificant coefficient, and an inverse correlation was found when the 18 regions were divided into four groups by increasing levels of Benomyl use. Parental occupation in agriculture did not seem to be associated with micro/anophthalmia when compared to a control group affected with isolated preauricular tags (odds ratio 0.63; CL 0.07–2.52). On the basis of these results, though the limits intrinsic to ecologic correlation studies must be taken into account, an association between Benomyl use and congenital micro/anophthalmia appears to be unlikely.
Article
Congenital microphthalmia (CMIC) (OMIM 309700) may occur in isolation or in association with a variety of systemic malformations. Isolated CMIC may be inherited as an autosomal dominant, an autosomal recessive, or an X-linked trait. On the basis of a whole-genome linkage analysis, we have mapped the first locus for isolated CMIC, in a five-generation consanguineous family with autosomal recessive inheritance, to chromosome 14q32. All affected individuals in this family have bilateral CMIC. Linkage analysis gave a maximum two-point LOD score of 3.55 for the marker D14S65. Surrounding this marker is a region of homozygosity of 7.3 cM, between the markers D14S987 and D14S267, within which the disease gene is predicted to lie. The genes for several eye-specific transcription factors are located on human chromosome 14q and in the syntenic region of mouse chromosome 12. However, both CHX10 (14q24.3), mutations of which give rise to CMIC in mouse models, and OTX2 (14q21-22) can be excluded as candidates for autosomal recessive congenital microphthalmia (arCMIC), since they map outside the critical disease region defined by recombination events. This suggests that arCMIC is caused by defects in a novel developmental gene that may be important or even essential in eye development.
Article
A Northern Ireland family is reported on, in which there is X-linked inheritance of clinical anophthalmos. Multi-point linkage analysis suggests that the gene is localized to the Xq27-28 region (Z = 1.9, Theta = 0.08), though not between the DNA markers DX13 and Factor VIII.
Article
This is a brief survey of more than 100 syndromes in which microphthalmos and/or coloboma appear. It is suggested that the disorders be assessed systematically by consecutive discussions of their aetiology, morphology and embryology.